Measles

Vaccine Journal Highlights the Potential for Self-Administration of Vaccines Using Vaxxas High-Density Microarray Patch (HD-MAP)

Retrieved on: 
Thursday, October 19, 2023

The publication outlines the potential for Vaxxas’ HD-MAP to enhance vaccine performance as well as increasing rates and acceptance of vaccination based on needle-free self-administration.

Key Points: 
  • The publication outlines the potential for Vaxxas’ HD-MAP to enhance vaccine performance as well as increasing rates and acceptance of vaccination based on needle-free self-administration.
  • The HD-MAP, upon which vaccines are ‘printed’ and dried, also provides storage and distribution benefits due to reduced cold chain requirements generally associated with vaccines delivered by needle and syringe.
  • Vaxxas is advancing a robust pipeline of pre-clinical and clinical stage HD-MAP vaccine candidates and has recently concluded multiple Phase I clinical studies.
  • The current Vaxxas pipeline targets COVID-19, seasonal and pandemic influenza, typhoid, measles and rubella, and cancer.

Calliditas Therapeutics to Present Seven Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023

Retrieved on: 
Thursday, October 19, 2023

STOCKHOLM, Oct. 19, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas"), today announced seven abstract presentations, including a late-breaking poster presentation, highlighting additional analyses of the Phase 3 NefIgArd study at the upcoming American Society of Nephrology (ASN) Kidney Week 2023 in Philadelphia, PA, November 1-5, 2023.

Key Points: 
  • STOCKHOLM, Oct. 19, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas"), today announced seven abstract presentations, including a late-breaking poster presentation, highlighting additional analyses of the Phase 3 NefIgArd study at the upcoming American Society of Nephrology (ASN) Kidney Week 2023 in Philadelphia, PA, November 1-5, 2023.
  • Poster presentation details are below and will be available on the Presentation and Publication page on the Calliditas' corporate website following the meeting.
  • It has not been established whether TARPEYO slows kidney function decline in patients with IgAN.
  • Continued approval for this indication may be contingent upon verification and description of clinical benefits in a confirmatory clinical trial.

Calliditas Therapeutics to Present Seven Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023

Retrieved on: 
Thursday, October 19, 2023

STOCKHOLM, Oct. 19, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas"), today announced seven abstract presentations, including a late-breaking poster presentation, highlighting additional analyses of the Phase 3 NefIgArd study at the upcoming American Society of Nephrology (ASN) Kidney Week 2023 in Philadelphia, PA, November 1-5, 2023.

Key Points: 
  • STOCKHOLM, Oct. 19, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas"), today announced seven abstract presentations, including a late-breaking poster presentation, highlighting additional analyses of the Phase 3 NefIgArd study at the upcoming American Society of Nephrology (ASN) Kidney Week 2023 in Philadelphia, PA, November 1-5, 2023.
  • Poster presentation details are below and will be available on the Presentation and Publication page on the Calliditas' corporate website following the meeting.
  • It has not been established whether TARPEYO slows kidney function decline in patients with IgAN.
  • Continued approval for this indication may be contingent upon verification and description of clinical benefits in a confirmatory clinical trial.

Global Adult Vaccines Market Research Report 2023: Market to Surpass $25 Billion by 2027 - Long-term Forecasts to 2032 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 11, 2023

Various technologies are harnessed to develop these vaccines, encompassing live attenuated vaccines, inactivated viral or bacterial vaccines, toxoid vaccines, recombinant vaccines, and conjugate vaccines.

Key Points: 
  • Various technologies are harnessed to develop these vaccines, encompassing live attenuated vaccines, inactivated viral or bacterial vaccines, toxoid vaccines, recombinant vaccines, and conjugate vaccines.
  • The adult vaccines market research report is an invaluable resource, offering a wealth of statistics on the adult vaccines market, including global market size, regional distributions, insights into market competitors with their respective market shares, comprehensive segmentation of the adult vaccines market, prevailing market trends, and promising opportunities.
  • These alarming statistics underscore the pivotal role of adult vaccines in curbing the spread of contagious diseases and substantiate the burgeoning growth of the adult vaccines market.
  • The adult vaccines market encompasses the sales of mRNA vaccines and viral vector vaccines.

Takeda Commits Over $30 Million in Five New Global CSR Partnerships To Further Drive Health Impact in 92 Countries

Retrieved on: 
Wednesday, September 13, 2023

Takeda ( TSE:4502/NYSE:TAK ) today announced five new partnerships to its Global Corporate Social Responsibility (CSR) Program, which contribute to strengthening health systems in low- and middle-income countries.

Key Points: 
  • Takeda ( TSE:4502/NYSE:TAK ) today announced five new partnerships to its Global Corporate Social Responsibility (CSR) Program, which contribute to strengthening health systems in low- and middle-income countries.
  • Takeda expects that Global CSR Program’s new five partnerships will bring its reach to 25.2 million people in 92 countries by 2028.
  • There are no quick fixes to global health challenges, which are complex, multi-dimensional and context dependent.
  • Health Information Systems: Developed, enhanced, or implemented 49 digital solutions, platforms, or tools to support data-informed health planning and health decision-making.

Global Vaccine Market Anticipated to Reach $92.32 Billion by 2028: Players Include GlaxoSmithKline, AstraZeneca, Sanofi Pasteur, Pfizer and CSL - ResearchAndMarkets.com

Retrieved on: 
Friday, September 8, 2023

Influenza vaccines reduce the risk of illness by 40% to 60% worldwide, including in the United States.

Key Points: 
  • Influenza vaccines reduce the risk of illness by 40% to 60% worldwide, including in the United States.
  • Emerging markets are witnessing a surge in demand for influenza vaccines due to high disease prevalence and limited access to vaccination.
  • Combo Vaccines: Combination vaccines that provide protection against multiple diseases with a single shot are gaining popularity.
  • Government initiatives, growing awareness of the benefits of vaccination, and advancements in vaccine technology have fueled their growth.

With COVID now endemic, modelling suggests targeted protection will be more effective than blanket measures

Retrieved on: 
Wednesday, August 23, 2023

In New Zealand, the government removed all remaining public health measures last week.

Key Points: 
  • In New Zealand, the government removed all remaining public health measures last week.
  • But although the emergency is over and the disease is rapidly becoming endemic, the risk of new variants remains.

The basic reproduction number

    • Back in 2020, we heard a lot about the basic reproduction number or R0.
    • This is the average number of people someone infects when the whole population is susceptible to the disease.
    • With a susceptible population, if R0 is above 1 the disease spreads exponentially.
    • This situation prompted governments around the world to implement intensive response measures, including lockdowns, to prevent health systems from becoming completely overwhelmed.

Controlling the disease

    • Effective control measures should reduce the number of contacts infectious people have, or the risk of infection per contact.
    • That’s certainly true, but how much effect do control measures realistically have for a virus like SARS-CoV-2?
    • But the effective reproduction number – the average number of people someone infects at the present time – is much closer to 1.

The maths of immunity

    • People may have acquired immunity through vaccination, but the protection vaccines provide against infection with current Omicron variants is relatively low and short-lived.
    • The majority of immunity comes from previous infections, including infections in vaccinated people.
    • (This doesn’t mean that getting infected to get immunity should ever be a goal, but it is an important side effect).
    • If R0=10, the maths is even more dismal: the same control measure only gives a 3% reduction in infections.

Targeted protection

    • The susceptible-immune binary is a simplification because immunity is not black and white but shades of grey.
    • Interventions targeted towards vulnerable groups are likely to be more effective than blanket measures.
    • Importantly, although reducing infection rates in the long term is difficult, vaccines provide direct protection for those who take them and continue to be highly effective at preventing severe disease.
    • He is an invited expert member of the Communicable Disease Network of Australia and between January 2020 and May 2022 was an invited expert member of the Australian Health Protection Principal Committee.

Grayson Perry: exploring what it is to be human with humour, irreverence and excess

Retrieved on: 
Thursday, August 10, 2023

Smash Hits, the new Grayson Perry retrospective at Edinburgh’s National Galleries, spans the 40-year career of the recently knighted artist.

Key Points: 
  • Smash Hits, the new Grayson Perry retrospective at Edinburgh’s National Galleries, spans the 40-year career of the recently knighted artist.
  • This makes a satisfying contrast with the highly polished style of his vases and the intricacy of his prints and tapestries.
  • Access to adult education, arts funding and affordable housing – some of the conditions that helped make Perry – have all been eroded.

Sympathetic heretic

    • His brand of self-mocking “iconclasm” is on parade in the print Map of Nowhere (2008).
    • This depicts Perry “as a God … A heavenly light shines out of my anus onto a mountaintop shrine”.
    • These lie at the heart of his work and are named in his discussion of his transformation through therapy.
    • It was about me putting on the clothes that gave me the feelings that I wanted.

Made in Britain

    • Another is the embroidery Britain is Best (2014) which depicts five men crammed on one horse, based on interviews with Unionists in Northern Ireland for his television series Who are You?.
    • “They seem to be holding out for an imagined Golden Age,” Perry muses.
    • Imagination, depicted as a river in Perry’s wonderful A Map of Days (2013) uproots oppressive states, inner and outer.
    • But to understand how the many might join him and thrive, rather than merely survive, we must look beyond the maps that Perry provides.

Conflict in Sudan Is Sparking a Humanitarian Emergency: Last Month 54,000 People Poured into South Sudan, Straining Already-Fragile Support Systems

Retrieved on: 
Tuesday, August 8, 2023

While some are Sudanese refugees, approximately 91% of the new arrivals are South Sudanese returnees, making them ineligible for international refugee programs.

Key Points: 
  • While some are Sudanese refugees, approximately 91% of the new arrivals are South Sudanese returnees, making them ineligible for international refugee programs.
  • Nonprofits like Action Against Hunger are helping the government screen and treat these returnees at transit stations designed for temporary stays.
  • The conflict also has stalled exports of South Sudanese oil through the port of Khartoum, weakening South Sudan's fragile economy and straining government coffers.
  • "Action Against Hunger is working to fill the gap, but it is incredibly difficult when humanitarian support is spread so thin."

Zuellig Pharma Singapore and GSK Establish Vaccine Distribution Hub to Improve Asia’s Access to Vaccines

Retrieved on: 
Tuesday, August 1, 2023

Under the partnership, Zuellig Pharma Singapore will provide GSK with warehousing and distribution services in cold-chain management for its vaccines.

Key Points: 
  • Under the partnership, Zuellig Pharma Singapore will provide GSK with warehousing and distribution services in cold-chain management for its vaccines.
  • The vaccine hub will also leverage Zuellig Pharma's expertise in blockchain technology for China, one of GSK's largest APAC markets.
  • Tan Yan Ann, Chief Executive, Zuellig Pharma Singapore said: "GSK has been a long-term partner of Zuellig Pharma with a strong focus on improving patients' access to healthcare.
  • The new vaccines distribution hub in Singapore will become our vaccine supply gateway into the region."